Profile data is unavailable for this security.
About the company
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
- Revenue in USD (TTM)0.00
- Net income in USD-55.94m
- Incorporated1996
- Employees51.00
- LocationAcumen Pharmaceuticals Inc427 PARK ST.CHARLOTTESVILLE 22902United StatesUSA
- Phone+1 (925) 368-8508
- Fax+1 (302) 636-5454
- Websitehttps://acumenpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | 0.00 | -44.78m | 169.04m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 169.62m | 93.00 | -- | 163.72 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 170.10m | 10.00 | -- | 0.8952 | -- | 85.05 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 171.51m | 147.00 | -- | -- | -- | 1.43 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| bluebird bio Inc | 21.73m | -91.17m | 171.97m | 323.00 | -- | 0.4345 | -- | 7.92 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 172.53m | 100.00 | -- | 6.21 | -- | 2.05 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -28.95m | 175.19m | 121.00 | -- | 2.22 | -- | -- | -0.4165 | -0.4165 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -26.50 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.0653 | -- | -- | -- | 13.64 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 176.63m | 51.00 | -- | 0.6741 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 177.09m | 53.00 | 11.40 | 3.82 | 10.47 | 3.74 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 178.39m | 459.00 | -- | -- | -- | 1.73 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 179.14m | 1.00 | -- | 59.39 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 179.26m | 22.00 | -- | 3.62 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 180.39m | 84.00 | -- | -- | -- | 51.54 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 180.69m | 101.00 | -- | 9.74 | -- | 6.67 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 181.02m | 25.00 | -- | 2.45 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 185.24m | 36.00 | 185.40 | 60.97 | 65.14 | 4.12 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Acumen Pharmaceuticals Inc's reporting currency: US Dollar USD
52.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 14.93m | 24.85% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 3.37m | 5.61% |
| Millennium Management LLCas of 31 Mar 2024 | 2.63m | 4.38% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 2.30m | 3.83% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.09m | 3.48% |
| Laurion Capital Management LPas of 31 Mar 2024 | 1.90m | 3.15% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.66m | 2.76% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.10m | 1.83% |
| Alyeska Investment Group LPas of 31 Mar 2024 | 939.60k | 1.56% |
| Jane Street Capital LLCas of 31 Mar 2024 | 600.26k | 1.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
